Präsenzveranstaltung
Issues: Cancer of the Pancreas and Bile Ducts, Interpreting Clinical Trials Results, Esophageal and Gastric Cancers, Diseases and Cancers of the Liver, Inflammation, Genetics, NETs and HCC, Carcinoma of unknown origin a.m.m.
Presentation of selected abstracts Colorectal Cancer:
Impact in prognosis of circulating tumor DNA mutant allele fraction (MAF) in RAS mutant metastatic colorectal cancer (mCRC)
Enrique Sanz-García, et al. O-010
RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)
Filippo Pietrantonio, et al. O-011
Impact of prior bevacizumab treatment of VEGFA and PIGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial
Eric Van Cutsem, et al. O-012
Presentation of selected abstracts New Drugs in GI Cancer and Abstracts on Non-Colorectal Cancer
Molecular variations between small bowel adenocarcinomas (SBAs), right-sided colon cancers (RT-Colon), and gastroesophageal cancers (GEC)
Mohamed Salem, et al., O-018
A phase Ib/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts)
Tanios Bekaii-Saab, et al., LBA-002
Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- Bevacizumab (bev) in metastatic colorectal cancer (mCRC) Patients (pts)
BH O’Neil, et al., LBA-003
Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)
G. Argilés, et al., LBA-004
Venue:
CCIB in Barcelona, Spain
"ESMO 19th World Congress on Gastrointestinal Cancer (19th WCGI)"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!